Search

Your search keyword '"Molenaar, Remco J."' showing total 213 results
Start Over Author "Molenaar, Remco J."
213 results on '"Molenaar, Remco J."'

1. T-cell redirecting bispecific antibody treatment in multiple myeloma: current knowledge and future strategies for sustained T-cell engagement

Author

Heerma van Voss, Marise R., Molenaar, Remco J., Korst, Charlotte L. B. M., Bartelink, Imke H., Baglio, Serena R., Kruyswijk, Sandy, de Ruijter, Maaike, Zweegman, Sonja, Kuipers, Maria T., and van de Donk, Niels W. C. J.

Abstract

ABSTRACTIntroductionT-cell redirecting bispecific antibodies (BsAbs), targeting B-cell maturation antigen (BCMA) or G-protein – coupled receptor class C group 5 member D (GPRC5D), are efficacious new agents for the treatment of patients with relapsed or refractory MM.Areas coveredThis review discusses the pharmacokinetic properties, efficacy, and safety profile of T-cell redirecting BsAbs in MM, with a special focus on their optimal dosing schedule, resistance mechanisms and future strategies to enhance efficacy, reduce toxicity, and maximize duration of response.Expert opinionTo further improve the efficacy of BsAbs, ongoing studies are investigating whether combination therapy can enhance depth and duration of response. An important open question is also to what extent response to BsAbs can be improved when these agents are used in earlier lines of therapy. In addition, more evidence is needed on rational de-intensification strategies of BsAb dosing upon achieving a sufficient response, and if (temporary) treatment cessation is possible in patients who have achieved a deep remission (e.g. complete response or minimal residual disease-negative status).

Published
2024
Full Text
View/download PDF

3. Risk of acute myeloid leukemia and myelodysplastic syndrome after autotransplants for lymphomas and plasma cell myeloma

Author

Radivoyevitch, Tomas, Dean, Robert M., Shaw, Bronwen E., Brazauskas, Ruta, Tecca, Heather R., Molenaar, Remco J., Battiwalla, Minoo, Savani, Bipin N., Flowers, Mary E.D., Cooke, Kenneth R., Hamilton, Betty K., Kalaycio, Matt, Maciejewski, Jaroslaw P., Ahmed, Ibrahim, Akpek, Görgün, Bajel, Ashish, Buchbinder, David, Cahn, Jean-Yves, D’Souza, Anita, Daly, Andrew, DeFilipp, Zachariah, Ganguly, Siddhartha, Hamadani, Mehdi, Hayashi, Robert J., Hematti, Peiman, Inamoto, Yoshihiro, Khera, Nandita, Kindwall-Keller, Tamila, Landau, Heather, Lazarus, Hillard, Majhail, Navneet S., Marks, David I., Olsson, Richard F., Seo, Sachiko, Steinberg, Amir, William, Basem M., Wirk, Baldeep, Yared, Jean A., Aljurf, Mahmoud, Abidi, Muneer H., Allewelt, Heather, Beitinjaneh, Amer, Cook, Rachel, Cornell, Robert F., Fay, Joseph W., Hale, Gregory, Chakrabarty, Jennifer Holter, Jodele, Sonata, Kasow, Kimberly A., Mahindra, Anuj, Malone, Adriana K., Popat, Uday, Rizzo, J. Douglas, Schouten, Harry C., Warwick, Anne B., Wood, William A., Sekeres, Mikkael A., Litzow, Mark R., Gale, Robert P., and Hashmi, Shahrukh K.

Published
2018
Full Text
View/download PDF

8. Data from Radioprotection of IDH1-Mutated Cancer Cells by the IDH1-Mutant Inhibitor AGI-5198

Author

Molenaar, Remco J., primary, Botman, Dennis, primary, Smits, Myrthe A., primary, Hira, Vashendriya V., primary, van Lith, Sanne A., primary, Stap, Jan, primary, Henneman, Peter, primary, Khurshed, Mohammed, primary, Lenting, Krissie, primary, Mul, Adri N., primary, Dimitrakopoulou, Dionysia, primary, van Drunen, Cornelis M., primary, Hoebe, Ron A., primary, Radivoyevitch, Tomas, primary, Wilmink, Johanna W., primary, Maciejewski, Jaroslaw P., primary, Vandertop, W. Peter, primary, Leenders, William P., primary, Bleeker, Fonnet E., primary, and van Noorden, Cornelis J., primary

Published
2023
Full Text
View/download PDF

9. Supplements from IDH1/2 Mutations Sensitize Acute Myeloid Leukemia to PARP Inhibition and This Is Reversed by IDH1/2-Mutant Inhibitors

Author

Molenaar, Remco J., primary, Radivoyevitch, Tomas, primary, Nagata, Yasunobu, primary, Khurshed, Mohammed, primary, Przychodzen, Bartolomiej, primary, Makishima, Hideki, primary, Xu, Mingjiang, primary, Bleeker, Fonnet E., primary, Wilmink, Johanna W., primary, Carraway, Hetty E., primary, Mukherjee, Sudipto, primary, Sekeres, Mikkael A., primary, van Noorden, Cornelis J.F., primary, and Maciejewski, Jaroslaw P., primary

Published
2023
Full Text
View/download PDF

10. Supplementary Table S1 from Radioprotection of IDH1-Mutated Cancer Cells by the IDH1-Mutant Inhibitor AGI-5198

Author

Molenaar, Remco J., primary, Botman, Dennis, primary, Smits, Myrthe A., primary, Hira, Vashendriya V., primary, van Lith, Sanne A., primary, Stap, Jan, primary, Henneman, Peter, primary, Khurshed, Mohammed, primary, Lenting, Krissie, primary, Mul, Adri N., primary, Dimitrakopoulou, Dionysia, primary, van Drunen, Cornelis M., primary, Hoebe, Ron A., primary, Radivoyevitch, Tomas, primary, Wilmink, Johanna W., primary, Maciejewski, Jaroslaw P., primary, Vandertop, W. Peter, primary, Leenders, William P., primary, Bleeker, Fonnet E., primary, and van Noorden, Cornelis J., primary

Published
2023
Full Text
View/download PDF

16. Cell Biology Meets Cell Metabolism: Energy Production Is Similar in Stem Cells and in Cancer Stem Cells in Brain and Bone Marrow

Author

van Noorden, Cornelis J.F., primary, Breznik, Barbara, additional, Novak, Metka, additional, van Dijck, Amber J., additional, Tanan, Saloua, additional, Vittori, Miloš, additional, Bogataj, Urban, additional, Bakker, Noëlle, additional, Khoury, Joseph D., additional, Molenaar, Remco J., additional, and Hira, Vashendriya V.V., additional

Published
2021
Full Text
View/download PDF

18. sj-pdf-1-jhc-10.1369_0022155421994679 – Supplemental material for Immunohistochemical Detection of Neural Stem Cells and Glioblastoma Stem Cells in the Subventricular Zone of Glioblastoma Patients

Author

Vashendriya V.V. Hira, Molenaar, Remco J., Breznik, Barbara, Lah, Tamara, Aronica, Eleonora, and Noorden, Cornelis J.F. Van

Subjects
FOS: Biological sciences, FOS: Clinical medicine, Cell Biology, 69999 Biological Sciences not elsewhere classified, 111599 Pharmacology and Pharmaceutical Sciences not elsewhere classified, nervous system diseases
Abstract

Supplemental material, sj-pdf-1-jhc-10.1369_0022155421994679 for Immunohistochemical Detection of Neural Stem Cells and Glioblastoma Stem Cells in the Subventricular Zone of Glioblastoma Patients by Vashendriya V.V. Hira, Remco J. Molenaar, Barbara Breznik, Tamara Lah, Eleonora Aronica and Cornelis J.F. Van Noorden in Journal of Histochemistry & Cytochemistry

Published
2021
Full Text
View/download PDF

19. sj-pdf-1-jhc-10.1369_00221554211054585 ��� Supplemental material for Cell Biology Meets Cell Metabolism: Energy Production Is Similar in Stem Cells and in Cancer Stem Cells in Brain and Bone Marrow

Author

van Noorden, Cornelis J.F., Breznik, Barbara, Novak, Metka, van Dijck, Amber J., Tanan, Saloua, Vittori, Milo��, Bogataj, Urban, Bakker, No��lle, Khoury, Joseph D., Molenaar, Remco J., and Hira, Vashendriya V.V.

Subjects
FOS: Biological sciences, FOS: Clinical medicine, Cell Biology, 69999 Biological Sciences not elsewhere classified, 111599 Pharmacology and Pharmaceutical Sciences not elsewhere classified
Abstract

Supplemental material, sj-pdf-1-jhc-10.1369_00221554211054585 for Cell Biology Meets Cell Metabolism: Energy Production Is Similar in Stem Cells and in Cancer Stem Cells in Brain and Bone Marrow by Cornelis J.F. van Noorden, Barbara Breznik, Metka Novak, Amber J. van Dijck, Saloua Tanan, Milo�� Vittori, Urban Bogataj, No��lle Bakker, Joseph D. Khoury, Remco J. Molenaar and Vashendriya V.V. Hira in Journal of Histochemistry & Cytochemistry

Published
2021
Full Text
View/download PDF

20. A Phase II Study Demonstrates No Feasibility of Adjuvant Treatment with Six Cycles of S-1 and Oxaliplatin in Resectable Esophageal Adenocarcinoma, with ERCC1 as Biomarker for Response to SOX

Author

MS Medische Oncologie, Cancer, MS CGO, Stroes, Charlotte I, Schokker, Sandor, Molenaar, Remco J, Mathôt, Ron A A, Bijlsma, Maarten F, van der Woude, Stephanie O, Belo Pereira, João P, Hooijer, Gerrit K J, Verhoeven, Rob H A, Cats, Annemieke, Grootscholten, Cecile, van Sandick, Johanna W, Creemers, Geert-Jan, Nieuwenhuijzen, Grard A P, Haj Mohammad, Nadia, Ruurda, Jelle P, Meijer, Sybren L, Hulshof, Maarten C C M, van Berge Henegouwen, Mark I, van Laarhoven, Hanneke W M, MS Medische Oncologie, Cancer, MS CGO, Stroes, Charlotte I, Schokker, Sandor, Molenaar, Remco J, Mathôt, Ron A A, Bijlsma, Maarten F, van der Woude, Stephanie O, Belo Pereira, João P, Hooijer, Gerrit K J, Verhoeven, Rob H A, Cats, Annemieke, Grootscholten, Cecile, van Sandick, Johanna W, Creemers, Geert-Jan, Nieuwenhuijzen, Grard A P, Haj Mohammad, Nadia, Ruurda, Jelle P, Meijer, Sybren L, Hulshof, Maarten C C M, van Berge Henegouwen, Mark I, and van Laarhoven, Hanneke W M

Published
2021

25. A Phase II Study Demonstrates No Feasibility of Adjuvant Treatment with Six Cycles of S-1 and Oxaliplatin in Resectable Esophageal Adenocarcinoma, with ERCC1 as Biomarker for Response to SOX

Author

Stroes, Charlotte I., primary, Schokker, Sandor, additional, Molenaar, Remco J., additional, Mathôt, Ron A. A., additional, Bijlsma, Maarten F., additional, van der Woude, Stephanie O., additional, Belo Pereira, João P., additional, Hooijer, Gerrit K. J., additional, Verhoeven, Rob H. A., additional, Cats, Annemieke, additional, Grootscholten, Cecile, additional, van Sandick, Johanna W., additional, Creemers, Geert-Jan, additional, Nieuwenhuijzen, Grard A. P., additional, Haj Mohammad, Nadia, additional, Ruurda, Jelle P., additional, Meijer, Sybren L., additional, Hulshof, Maarten C. C. M., additional, van Berge Henegouwen, Mark I., additional, and van Laarhoven, Hanneke W. M., additional

Published
2021
Full Text
View/download PDF

29. Phase II Feasibility and Biomarker Study of Neoadjuvant Trastuzumab and Pertuzumab With Chemoradiotherapy for Resectable Human Epidermal Growth Factor Receptor 2–Positive Esophageal Adenocarcinoma: TRAP Study

Author

Stroes, Charlotte I., primary, Schokker, Sandor, additional, Creemers, Aafke, additional, Molenaar, Remco J., additional, Hulshof, Maarten C.C.M., additional, van der Woude, Stephanie O., additional, Bennink, Roel J., additional, Mathôt, Ron A.A., additional, Krishnadath, Kausilia K., additional, Punt, Cornelis J.A., additional, Verhoeven, Rob H.A., additional, van Oijen, Martijn G.H., additional, Creemers, Geert-Jan, additional, Nieuwenhuijzen, Grard A.P., additional, van der Sangen, Maurice J.C., additional, Beerepoot, Laurens V., additional, Heisterkamp, Joos, additional, Los, Maartje, additional, Slingerland, Marije, additional, Cats, Annemieke, additional, Hospers, Geke A.P., additional, Bijlsma, Maarten F., additional, van Berge Henegouwen, Mark I., additional, Meijer, Sybren L., additional, and van Laarhoven, Hanneke W.M., additional

Published
2020
Full Text
View/download PDF

31. IDH1/2 Mutations in Cancer Stem Cells and Their Implications for Differentiation Therapy.

Author

Molenaar, Remco J. and Wilmink, Johanna W.

Subjects
CANCER stem cells, CANCER cell differentiation, CELL differentiation, ISOCITRATE dehydrogenase, ACUTE myeloid leukemia, CANCER cells
Abstract

Isocitrate dehydrogenase 1 and 2 (IDH1/2) are enzymes recurrently mutated in various types of cancer, including glioma, cholangiocarcinoma, chondrosarcoma, and acute myeloid leukemia. Mutant IDH1/2 induce a block in differentiation and thereby contribute to the stemness and oncogenesis of their cells of origin. Recently, small-molecule inhibitors of mutant IDH1/2 have been Food and Drug Administration–approved for the treatment of IDH1/2 -mutated acute myeloid leukemia. These inhibitors decrease the stemness of the targeted IDH1/2 -mutated cancer cells and induce their differentiation to more mature cells. In this review, we elucidate the mechanisms by which mutant IDH1/2 induce a block in differentiation and the biological and clinical effects of the release into differentiation by mutant-IDH1/2 inhibitors. (J Histochem Cytochem 70:83–97, 2022) [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

32. Cell Biology Meets Cell Metabolism: Energy Production Is Similar in Stem Cells and in Cancer Stem Cells in Brain and Bone Marrow.

Author

van Noorden, Cornelis J.F., Breznik, Barbara, Novak, Metka, van Dijck, Amber J., Tanan, Saloua, Vittori, Miloš, Bogataj, Urban, Bakker, Noëlle, Khoury, Joseph D., Molenaar, Remco J., and Hira, Vashendriya V.V.

Subjects
CANCER stem cells, BONE marrow cells, NEURAL stem cells, CYTOLOGY, CELLULAR control mechanisms, CELL metabolism, GLYCOLYSIS
Abstract

Energy production by means of ATP synthesis in cancer cells has been investigated frequently as a potential therapeutic target in this century. Both (an)aerobic glycolysis and oxidative phosphorylation (OXPHOS) have been studied. Here, we review recent literature on energy production in glioblastoma stem cells (GSCs) and leukemic stem cells (LSCs) versus their normal counterparts, neural stem cells (NSCs) and hematopoietic stem cells (HSCs), respectively. These two cancer stem cell types were compared because their niches in glioblastoma tumors and in bone marrow are similar. In this study, it became apparent that (1) ATP is produced in NSCs and HSCs by anaerobic glycolysis, whereas fatty acid oxidation (FAO) is essential for their stem cell fate and (2) ATP is produced in GSCs and LSCs by OXPHOS despite the hypoxic conditions in their niches with FAO and amino acids providing its substrate. These metabolic processes appeared to be under tight control of cellular regulation mechanisms which are discussed in depth. However, our conclusion is that systemic therapeutic targeting of ATP production via glycolysis or OXPHOS is not an attractive option because of its unwanted side effects in cancer patients. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

33. The Effect of Metformin on Bladder Cancer Incidence and Outcomes: A Systematic Review and Meta-Analysis

Author

van Hattum, Jons W., de Ruiter, Ben Max, Oddens, Jorg R., de Reijke, Theo M., Wilmink, Johanna W., and Molenaar, Remco J.

Abstract

Effective oral treatment options for urothelial bladder cancer (BC) are lacking. Metformin, the most frequently used oral drug in type II diabetes mellitus, has putative anticancer properties and could, therefore, influence BC incidence and treatment outcomes. We systematically reviewed the current literature regarding the effect of metformin on BC incidence and oncological outcomes in non-muscle-invasive bladder cancer (NMIBC) and muscle-invasive bladder cancer (MIBC). This review was conducted according to the PRISMA guidelines. Literature was gathered through a systematic search in PubMed/Medline, EMBASE and the Cochrane library. Risk of bias was determined using the Cochrane risk-of-bias tool for randomized trials and the Newcastle-Ottawa Scale for non-randomized trials. Hazard ratios (HRs) were extracted and pooled in a random-effects meta-analysis. We reviewed 13 studies, including 3,315,320 patients, considering the risk of developing BC after metformin exposure and 9 studies, including 4,006 patients, on oncological outcomes of patients with BC. Metformin did not affect BC incidence (HR 0.97, 95% CI 0.87 –1.09) or oncological outcomes for NMIBC but did show a reduced risk of recurrence (HR 0.52, 95% CI 0.32 –0.84), cancer-specific mortality (HR 0.58, 95% CI 0.43 –0.78) and overall mortality (HR 0.66, 95% CI 0.47 –0.92) in MIBC. The role of metformin in the prevention and treatment of BC in patients remains unclear. Although a beneficial effect of metformin on treatment outcomes of certain stages of BC may exist, a definitive conclusion cannot be drawn. Prospective clinical trials are needed to assess the efficacy of metformin for BC treatment.

Published
2022
Full Text
View/download PDF

34. DS_10.1369_0022155419878416 – Supplemental material for Similarities Between Stem Cell Niches in Glioblastoma and Bone Marrow: Rays of Hope for Novel Treatment Strategies

Author

Vashendriya V.V. Hira, Breznik, Barbara, Miloš Vittori, Jong, Annique Loncq De, Mlakar, Jernej, Roelof-Jan Oostra, Khurshed, Mohammed, Molenaar, Remco J., Lah, Tamara, and Noorden, Cornelis J.F. Van

Subjects
FOS: Biological sciences, FOS: Clinical medicine, Cell Biology, 69999 Biological Sciences not elsewhere classified, 111599 Pharmacology and Pharmaceutical Sciences not elsewhere classified
Abstract

Supplemental material, DS_10.1369_0022155419878416 for Similarities Between Stem Cell Niches in Glioblastoma and Bone Marrow: Rays of Hope for Novel Treatment Strategies by Vashendriya V.V. Hira, Barbara Breznik, Miloš Vittori, Annique Loncq de Jong, Jernej Mlakar, Roelof-Jan Oostra, Mohammed Khurshed, Remco J. Molenaar, Tamara Lah and Cornelis J.F. Van Noorden in Journal of Histochemistry & Cytochemistry

Published
2019
Full Text
View/download PDF

39. Study protocol of a phase IB/II clinical trial of metformin and chloroquine in patients with -mutated or -mutated solid tumours

Author

Molenaar, Remco J, Coelen, Robert J S, Khurshed, Mohammed, Roos, Eva, Caan, Matthan W A, van Linde, Myra E, Kouwenhoven, Mathilde, Bramer, Jos A M, Bovée, Judith V M G, Mathôt, Ron A, Klümpen, Heinz-Josef, van Laarhoven, Hanneke W M, van Noorden, Cornelis J F, Vandertop, W Peter, Gelderblom, Hans, van Gulik, Thomas M, Wilmink, Johanna W, Medical oncology, CCA - Cancer Treatment and quality of life, Neurology, and Neurosurgery

Abstract

INTRODUCTION: High-grade chondrosarcoma, high-grade glioma and intrahepatic cholangiocarcinoma are aggressive types of cancer with a dismal outcome. This is due to the lack of effective treatment options, emphasising the need for novel therapies. Mutations in the genes IDH1 and IDH2 (isocitrate dehydrogenase 1 and 2) occur in 60% of chondrosarcoma, 80% of WHO grade II-IV glioma and 20% of intrahepatic cholangiocarcinoma. IDH1/2-mutated cancer cells produce the oncometabolite D-2-hydroxyglutarate (D-2HG) and are metabolically vulnerable to treatment with the oral antidiabetic metformin and the oral antimalarial drug chloroquine.METHODS AND ANALYSIS: We describe a dose-finding phase Ib/II clinical trial, in which patients with IDH1/2-mutated chondrosarcoma, glioma and intrahepatic cholangiocarcinoma are treated with a combination of metformin and chloroquine. Dose escalation is performed according to a 3+3 dose-escalation scheme. The primary objective is to determine the maximum tolerated dose to establish the recommended dose for a phase II clinical trial. Secondary objectives of the study include (1) determination of pharmacokinetics and toxic effects of the study therapy, for which metformin and chloroquine serum levels will be determined over time; (2) investigation of tumour responses to metformin plus chloroquine in IDH1/2-mutated cancers using CT/MRI scans; and (3) whether tumour responses can be measured by non-invasive D-2HG measurements (mass spectrometry and magnetic resonance spectroscopy) of tumour tissue, serum, urine, and/or bile or next-generation sequencing of circulating tumour DNA (liquid biopsies). This study may open a novel treatment avenue for IDH1/2-mutated high-grade chondrosarcoma, glioma and intrahepatic cholangiocarcinoma by repurposing the combination of two inexpensive drugs that are already approved for other indications.ETHICS AND DISSEMINATION: This study has been approved by the medical-ethical review committee of the Academic Medical Center, Amsterdam, The Netherlands. The report will be submitted to a peer-reviewed journal.TRIAL REGISTRATION NUMBER: This article was registered at ClinicalTrials.gov identifier (NCT02496741): Pre-results.

Published
2017

41. Similarities Between Stem Cell Niches in Glioblastoma and Bone Marrow: Rays of Hope for Novel Treatment Strategies.

Author

Hira, Vashendriya V.V., Breznik, Barbara, Vittori, Miloš, Loncq de Jong, Annique, Mlakar, Jernej, Oostra, Roelof-Jan, Khurshed, Mohammed, Molenaar, Remco J., Lah, Tamara, and Van Noorden, Cornelis J.F.

Subjects
CANCER stem cells, GLIOBLASTOMA multiforme, BONE marrow, CANCER relapse, ACUTE myeloid leukemia
Abstract

Glioblastoma is the most aggressive primary brain tumor. Slowly dividing and therapy-resistant glioblastoma stem cells (GSCs) reside in protective peri-arteriolar niches and are held responsible for glioblastoma recurrence. Recently, we showed similarities between GSC niches and hematopoietic stem cell (HSC) niches in bone marrow. Acute myeloid leukemia (AML) cells hijack HSC niches and are transformed into therapy-resistant leukemic stem cells (LSCs). Current clinical trials are focussed on removal of LSCs out of HSC niches to differentiate and to become sensitized to chemotherapy. In the present study, we elaborated further on these similarities by immunohistochemical analyses of 17 biomarkers in paraffin sections of human glioblastoma and human bone marrow. We found all 17 biomarkers to be expressed both in hypoxic peri-arteriolar HSC niches in bone marrow and hypoxic peri-arteriolar GSC niches in glioblastoma. Our findings implicate that GSC niches are being formed in glioblastoma as a copy of HSC niches in bone marrow. These similarities between HSC niches and GSC niches provide a theoretic basis for the development of novel strategies to force GSCs out of their niches, in a similar manner as in AML, to induce GSC differentiation and proliferation to render them more sensitive to anti-glioblastoma therapies. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

42. Somatic Mutations in Therapy-Related Myeloid Neoplasms Are Influenced By Therapeutic Modality and Clonal Hematopoiesis of Indeterminate Potential

Author

Kuzmanovic, Teodora, primary, Patel, Bhumika J., additional, Sanikommu, Srinivasa Reddy, additional, Nagata, Yasunobu, additional, Awada, Hassan, additional, Hirsch, Cassandra M., additional, Przychodzen, Bartlomiej P., additional, Molenaar, Remco J, additional, Jha, Babal K., additional, Mukherjee, Sudipto, additional, Advani, Anjali S., additional, Nazha, Aziz, additional, Gerds, Aaron T., additional, Carraway, Hetty E., additional, Sekeres, Mikkael A., additional, Maciejewski, Jaroslaw P., additional, and Radivoyevitch, Tomas, additional

Published
2018
Full Text
View/download PDF

43. Is There an Increased Risk of ALL in Patients with First Cancers Treated with Radiotherapy and/or Chemotherapy?

Author

Molenaar, Remco J, primary, Radivoyevitch, Tomas, additional, Gerds, Aaron T., additional, Nazha, Aziz, additional, Carraway, Hetty E., additional, Advani, Anjali S., additional, Kalaycio, Matt, additional, Majhail, Navneet S., additional, Maciejewski, Jaroslaw P., additional, Sekeres, Mikkael A., additional, and Mukherjee, Sudipto, additional

Published
2018
Full Text
View/download PDF

44. Isocitrate dehydrogenase 1–mutated human gliomas depend on lactate and glutamate to alleviate metabolic stress

Author

Lenting, Krissie, primary, Khurshed, Mohammed, additional, Peeters, Tom H., additional, Heuvel, Corina N. A. M., additional, Lith, Sanne A. M., additional, Bitter, Tessa, additional, Hendriks, Wiljan, additional, Span, Paul N., additional, Molenaar, Remco J., additional, Botman, Dennis, additional, Verrijp, Kiek, additional, Heerschap, Arend, additional, Laan, Mark, additional, Kusters, Benno, additional, Ewijk, Anne, additional, Huynen, Martijn A., additional, Noorden, Cornelis J. F., additional, and Leenders, William P. J., additional

Published
2018
Full Text
View/download PDF

46. Reply to A. Piccardo et al, E. Hindié et al, M.C. Kreissl et al, M. Doss, J. Buscombe, R. Fisher, M. Sollini et al, M. Lichtenstein, and M. Tulchinsky et al

Author

Molenaar, Remco J., primary, Sidana, Surbhi, additional, Radivoyevitch, Tomas, additional, Gerds, Aaron T., additional, Carraway, Hetty E., additional, Kalaycio, Matt, additional, Nazha, Aziz, additional, Adelstein, David J., additional, Nasr, Christian, additional, Maciejewski, Jaroslaw P., additional, Majhail, Navneed S., additional, Sekeres, Mikkael A., additional, and Mukherjee, Sudipto, additional

Published
2018
Full Text
View/download PDF

47. Risk of Hematologic Malignancies After Radioiodine Treatment of Well-Differentiated Thyroid Cancer

Author

Molenaar, Remco J., primary, Sidana, Surbhi, additional, Radivoyevitch, Tomas, additional, Advani, Anjali S., additional, Gerds, Aaron T., additional, Carraway, Hetty E., additional, Angelini, Dana, additional, Kalaycio, Matt, additional, Nazha, Aziz, additional, Adelstein, David J., additional, Nasr, Christian, additional, Maciejewski, Jaroslaw P., additional, Majhail, Navneet S., additional, Sekeres, Mikkael A., additional, and Mukherjee, Sudipto, additional

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results